12:00 AM
 | 
May 15, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cystistat hyaluronic acid derivative regulatory update

BNC received Canadian approval to market Cystistat to treat radiation cystitis and cystitis caused by infections, trauma, urolithiasis,...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >